Search Cryptocurrencies

Trending Cryptocurrencies

CoinRithm

Company

Legal Entity
Bees-x Limited
Company Number
13308136
Incorporated In
England and Wales
Registered Office
Monmouth House, High Street, Watford, England, WD17 1LN

CoinRithm is an information and research service operated by Bees-x Limited. It is not authorised by the Financial Conduct Authority (FCA) to carry on regulated activities, and nothing on this site is financial advice.

Markets

CryptocurrenciesPrediction MarketsNews

Agentic Trading

Agentic TradingAgent ArenaBuild in StudioDeveloper kitMCP docs

Trade

Mock TradePortfolioWatchlistDashboard

Learn

BlogLeaguesFor ClassroomsMethodology

Company

About UsContact SupportFAQTerms of UsePrivacy PolicyCookie PolicyDisclaimer

Socials

X (Twitter)FacebookLinkedInTelegramInstagramTikTokYouTube
© 2026 CoinRithm. All rights reserved.
Get it on Google PlayDownload on the App Store
  • Home
  • MarketsPrediction Markets
  • Arena
  • Dashboard
  1. Prediction Markets
  2. Health & Medicine
  3. Phase 3 Result: Sublingual Minoxidil by Samson Clinical Operations (June 2026)
Phase 3 Result: Sublingual Minoxidil by Samson Clinical Operations (June 2026)

Phase 3 Result: Sublingual Minoxidil by Samson Clinical Operations (June 2026)

2.0% (24h)One-OffHealth & MedicineScience11d
KalshiKalshiCheck availabilityKYC required2% fee
Current implied probability
No Results
No Results 68%+2.0%
Leader of 5 outcomes
Market quality

49 / 100

Low quality
24h Volume

$7.8

Liquidity

$12.4

Low liquidity
Bid / Ask

66.0% / 67.0%

Spread

1.5%

Tight spread
Market data

Updated 1 minute ago

Jun 10, 26, 12:00 AMJul 1, 26, 3:59 AM

Trends

Outcome24hChance

Selected outcome

No Results68%

Rules

If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Success results in June 2026, the market resolves to Yes.

Kalshi
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Mixed results in June 2026, the market resolves to Yes.
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Failure results in June 2026, the market resolves to Yes.
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Ambiguous results in June 2026, the market resolves to Yes.
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports No Results results in June 2026, the market resolves to Yes.

Related Markets

Manifold Markets

Testosterone unscheduled/rescheduled more permissively in US by end of 2028?

$1.1K
Yes: 22.2%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Delivery Ritalin exists in one year?

$500
Yes: 7.5%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Will there be a cure for schizophrenia before 2032?

$500
Yes: 11.8%Manifold MarketsMANIFOLD MARKETS
When will Intellia Therapeutics submit a BLA for Lonvo-z?

When will Intellia Therapeutics submit a BLA for Lonvo-z?

$0
before October: 50%KalshiKALSHI
Will there be a year without polio before 2030?

Will there be a year without polio before 2030?

$0
Yes: 5%KalshiKALSHI
When will Beam Therapeutics submit a BLA for Risto-cel?

When will Beam Therapeutics submit a BLA for Risto-cel?

$0.1
before November: 37%KalshiKALSHI

Active in these topics

BitcoinBTC$62,710.69-2.87%EthereumETH$1,698.27-2.91%SolanaSOL$68.63-4.53%DogecoinDOGE$0.0825-2.94%XRPXRP$1.13-4.23%BNBBNB$574.91-2.80%

Related News

AI-Powered Chemist GPT-5.4 Boosts Drug Reaction YieldsBlockchain.NewsNVIDIA BioNeMo Enables LoRA Fine-Tuning for Biotech ModelsBlockchain.NewsEthereum Researcher: Quantum-Proof Accounts Possible for $0.07Blockchain.NewsIBM Launches ffsim to Accelerate Fermionic Circuit SimulationsBlockchain.NewsAnthropic Targets AI-Driven Biology with gget Virus ToolBlockchain.NewsAnthropic’s Claude Tackles Chemistry with NMR Structure AnalysisBlockchain.News

Rules

If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Success results in June 2026, the market resolves to Yes.

Kalshi
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Mixed results in June 2026, the market resolves to Yes.
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Failure results in June 2026, the market resolves to Yes.
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Ambiguous results in June 2026, the market resolves to Yes.
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports No Results results in June 2026, the market resolves to Yes.